Literature DB >> 10494295

Risk and prognosis in renal neoplasms. A pathologist's prospective.

S M Bonsib1.   

Abstract

The incidence of renal carcinoma has increased in the United States over the last two decades. An increased rate of detection of incidental tumors and a variety of exogenous risk factors may be responsible for this increase. Pathologic stage and nuclear grade remain the most important and practical prognostic features, however, the specific tumor type has emerged as important as the cytogenetic validation of recent renal carcinoma classification. Proliferation markers, DNA ploidy, and morphometry have powerful predictive value but are handicapped by cost and complexity. The search continues for molecules of diagnostic and prognostic utility that may also impact invasive and metastatic capability for this group of neoplasms whose course is principally determined by the completeness of the original resection.

Entities:  

Mesh:

Year:  1999        PMID: 10494295     DOI: 10.1016/s0094-0143(05)70205-6

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  4 in total

1.  Multimodality Imaging Characteristics of the Common Renal Cell Carcinoma Subtypes: An Analysis of 544 Pathologically Proven Tumors.

Authors:  Winnie Fu; Guan Huang; Zaahir Moloo; Safwat Girgis; Vimal H Patel; Gavin Low
Journal:  J Clin Imaging Sci       Date:  2016-12-29

2.  Pan-Renal Cell Carcinoma classification and survival prediction from histopathology images using deep learning.

Authors:  Sairam Tabibu; P K Vinod; C V Jawahar
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

3.  Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.

Authors:  Mi Tian; Tao Wang; Peng Wang
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

4.  Immunohistochemical study of C-kit expression in subtypes of renal cell carcinoma.

Authors:  Farahnaz Norouzinia; Fariba Abbasi; Sina Dindarian; Sedra Mohammadi; Farid Meisami; Mahdi Bagheri; Hozan Mohammadi
Journal:  Turk J Urol       Date:  2018-01-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.